Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of composition containing ginsenoside Rg1 and fucoidin in preparation of medicine for reducing expression of tissue factors

A technology of fucoidan and ginsenoside, which is applied in the field of peripheral neuropathy compositions, can solve problems such as complex mechanisms, achieve the effects of inhibiting overexpression, enhancing resistance, and improving microcirculation disorders

Active Publication Date: 2022-02-08
NANJING MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complexity of the mechanism of CIPN and the limitations of existing therapeutic drugs, finding new therapeutic drugs has become an urgent clinical problem to be solved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition containing ginsenoside Rg1 and fucoidin in preparation of medicine for reducing expression of tissue factors
  • Application of composition containing ginsenoside Rg1 and fucoidin in preparation of medicine for reducing expression of tissue factors
  • Application of composition containing ginsenoside Rg1 and fucoidin in preparation of medicine for reducing expression of tissue factors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] A composition for treating chemotherapy-induced peripheral neuropathy, which is composed of ginsenoside Rg1 and fucoidan, the purity of ginsenoside Rg1 is ≥95%, the purity of fucoidan is ≥95%, and there is no special requirement for particle size and diameter. The mass ratio of ginsenoside Rg1 to fucoidan is 1:1.

[0033]Preparation method: Dissolve 40mg of ginsenoside Rg1 powder and 40mg of fucoidan powder in 5ml of sterile water, shake and vortex, mix and dissolve completely.

Embodiment 2

[0035] A composition for treating chemotherapy-induced peripheral neuropathy, which is composed of ginsenoside Rg1 and fucoidan, the purity of ginsenoside Rg1 is ≥95%, the purity of fucoidan is ≥95%, and there is no special requirement for particle size and diameter. The mass ratio of ginsenoside Rg1 to fucoidan is 1:5.

[0036] Preparation method: Dissolve 40mg of ginsenoside Rg1 powder and 200mg of fucoidan powder in 5ml of sterile water, shake and vortex, mix and dissolve completely.

Embodiment 3

[0038] A composition for treating chemotherapy-induced peripheral neuropathy, which is composed of ginsenoside Rg1 and fucoidan, the purity of ginsenoside Rg1 is ≥95%, the purity of fucoidan is ≥95%, and there is no special requirement for particle size and diameter. The mass ratio of ginsenoside Rg1 to fucoidan is 1:2.5.

[0039] Preparation method: Dissolve 40mg of ginsenoside Rg1 powder and 100mg of fucoidan powder in 5ml of sterile water, shake and vortex to mix and dissolve completely.

[0040] Evaluation of the effect of the composition of the present invention in treating CIPN

[0041] Experimental program:

[0042] 1 Experimental animals: male C57BL / 6J mice and male ICR mice, SPF grade, 6-8 weeks old, provided by the Experimental Animal Management Department of Shanghai Institute of Family Planning Sciences, SR-AKO mice were provided by Chen Qi, Nanjing Medical University Gifted by the professor, reproduced in the Experimental Animal Center of Nanjing Medical Univers...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composition for treating peripheral neuropathy induced by chemotherapy and application of the composition, and belongs to the field of medicines. The composition for treating the peripheral neuropathy induced by chemotherapy, provided by the invention, comprises ginsenoside Rg1 and fucoidin. According to the invention, the composition can be used for remarkably inhibiting the expression of proinflammatory factors such as TNF-alpha, IL-1beta, IL-6 and the like, so that the effects of resisting inflammation, promoting repair and enhancing resistance are generated on peripheral nerves; and the composition can remarkably improve microcirculation disturbance and up-regulate SR-A expression, so that the capability of phagocytosis and elimination of macrophages on HMGB1 is enhanced, TF overexpression is inhibited, microcirculation disturbance and neuropathic pain caused by chemotherapy drugs are relieved in a multi-target and multi-mechanism mode, and development of CIPN is inhibited fundamentally so as to achieve the safe and effective treatment purpose and provide a new treatment strategy for clinic.

Description

[0001] This application is a divisional application with an application date of December 11, 2020, an application number of 202011457399.8, and an invention title of "A Composition for Treating Chemotherapy-Induced Peripheral Neuropathy and Its Application". technical field [0002] The invention belongs to the field of medicine, and in particular relates to a composition for treating chemotherapy-induced peripheral neuropathy and application thereof. Background technique [0003] Tumor is a disease that seriously endangers human health, and its treatment is very difficult. Although there are some targeted drug treatments, chemotherapy is still one of the most commonly used means of treating malignant tumors. Sadly, chemotherapy often comes with serious side effects, such as pain, vomiting, dizziness, and hair loss. Pain, in particular, will make patients more anxious or even depressed, which will seriously affect the patient's mental state and ultimately hinder the treatme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61K31/704A61P25/02A61P29/00
CPCA61K31/704A61K31/715A61P25/02A61P43/00A61K2300/00Y02A50/30
Inventor 刘文涛陈琪李岩姜春懿胡亮吴雪丰王玉林彤彤贾茹梦
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com